Eton Pharmaceuticals Inc (ETON)
NASDAQ:ETON
Want to see ETON full AI Analyst Report?
ETON Stock Chart & Stats
$26.97
-$0.03(-0.25%)
At close: 4:00 PM EST
$26.97
-$0.03(-0.25%)
Day’s Range― - ―
52-Week Range$13.09 - $27.29
Previous CloseN/A
Volume127.06K
Average Volume (3M)416.10K
Market Cap
$735.86M
Enterprise Value$719.17M
Total Cash (Recent Filing)$25.94M
Total Debt (Recent Filing)$9.25M
Price to Earnings (P/E)76.7
Beta0.90
Next Earnings
May 07, 2026EPS Estimate
0.11Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.05
Shares Outstanding27,284,490
10 Day Avg. Volume436,384
30 Day Avg. Volume416,096
Financial Highlights & Ratios
PEG Ratio-7.42
Price to Book (P/B)17.40
Price to Sales (P/S)5.69
P/FCF Ratio44.65
Enterprise Value/Market Cap0.98
Enterprise Value/Revenue9.00
Enterprise Value/Gross Profit16.83
Enterprise Value/Ebitda187.92
Forecast
1Y Price Target
$39.33Price Target Upside45.83% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)1.02
Revenue Forecast (FY)$105.27M
Bulls Say, Bears Say
Bulls Say
Commercial Launch ExecutionA commercial launch that leverages a specialty pharmacy for distribution and an established pediatric rare disease sales force can facilitate targeted access to specialty providers and accelerate uptake in orphan markets.
Formulation And Dosing AdvantageAn oral liquid formulation enables more precise and flexible dosing than tablets and can attract patients and caregivers who prefer liquid medication, reducing dosing challenges for those needing adjusted doses.
Regulatory Label ExpansionA broad FDA label without age restrictions expands the drug's addressable market to include adult patients as well as pediatric patients, increasing potential patient population and revenue opportunities.
Bears Say
Adult Market Penetration RiskPenetration into the adult population may be lower than in pediatrics, which could limit expected market expansion and revenue upside from broader labeling.
Eton Pharmaceuticals News
ETON FAQ
What was Eton Pharmaceuticals Inc’s price range in the past 12 months?
Eton Pharmaceuticals Inc lowest stock price was $13.09 and its highest was $27.29 in the past 12 months.
What is Eton Pharmaceuticals Inc’s market cap?
Eton Pharmaceuticals Inc’s market cap is $735.86M.
When is Eton Pharmaceuticals Inc’s upcoming earnings report date?
Eton Pharmaceuticals Inc’s upcoming earnings report date is May 07, 2026 which is in 21 days.
How were Eton Pharmaceuticals Inc’s earnings last quarter?
Eton Pharmaceuticals Inc released its earnings results on Mar 19, 2026. The company reported $0.05 earnings per share for the quarter, missing the consensus estimate of $0.133 by -$0.083.
Is Eton Pharmaceuticals Inc overvalued?
According to Wall Street analysts Eton Pharmaceuticals Inc’s price is currently Undervalued.
Does Eton Pharmaceuticals Inc pay dividends?
Eton Pharmaceuticals Inc does not currently pay dividends.
What is Eton Pharmaceuticals Inc’s EPS estimate?
Eton Pharmaceuticals Inc’s EPS estimate is 0.11.
How many shares outstanding does Eton Pharmaceuticals Inc have?
Eton Pharmaceuticals Inc has 27,284,490 shares outstanding.
What happened to Eton Pharmaceuticals Inc’s price movement after its last earnings report?
Eton Pharmaceuticals Inc reported an EPS of $0.05 in its last earnings report, missing expectations of $0.133. Following the earnings report the stock price went up 7.463%.
Which hedge fund is a major shareholder of Eton Pharmaceuticals Inc?
Currently, no hedge funds are holding shares in ETON
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Eton Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$39.33 (45.83% Upside)
$39.33 (45.83% Upside)
Blogger Sentiment
Bullish
ETON Sentiment 75%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 86.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $132.6K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.7%
Last 30 Days ▲ 26.2%
Last 30 Days ▲ 26.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
97.66%
12-Months-Change
Fundamentals
Return on Equity
-18.84%
Trailing 12-Months
Asset Growth
21.01%
Trailing 12-Months
Company Description
Eton Pharmaceuticals Inc
Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing pharmaceutical products for rare diseases. The company offers Biorphen, a phenylephrine injection for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; and Rezipres, a ready-to-use formulation of a molecule that is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia. It also offers Alkindi Sprinkle, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; EPRONTIA, a liquid formulation of topiramate; and Alaway Preservative Free, a preservative-free ophthalmic product to treat allergic conjunctivitis. In addition, the company develops Zonisamide Oral Suspension for the treatment of partial on-set seizures; Lamotrigine for Oral Suspension for the treatment of partial on-set seizures; cysteine injection; dehydrated alcohol injection; and Zeneo hydrocortisone autoinjector. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.
ETON Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call communicated a strong operational and financial momentum: substantial revenue growth (Q4 +83% YoY), material margin improvement (adjusted EBITDA margin up to 29%), multiple successful launches (Desmota, Galzin relaunch) and an accretive cash acquisition (Hemangiol). Management provided ambitious but concrete 2026 guidance (> $110M revenue, ≥30% adjusted EBITDA margin) and laid out multi-year targets that tie commercial execution to margin expansion. Near-term headwinds include Q4 cash outflow driven by large Medicaid rebates and newly triggered FDA program fees, some margin volatility from ex-U.S. Incralex orders, and execution/timing risks around label expansions and clinical studies. Overall, the positives—rapid revenue scaling, improving profitability, multiple product launch catalysts, and a strengthened pipeline—appear to significantly outweigh the manageable near-term financial and execution risks.View all ETON earnings summariesETON Stock 12 Month Forecast
Average Price Target
$39.33
▲(45.83% Upside)
Technical Analysis
Ownership Overview
25.56% Insiders
8.18% Mutual Funds
31.20% Other Institutional Investors
26.61% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---